AngioScore, a Fremont, Calif.-based endovascular company, has successfully completed a $30 million private equity financing.

Telegraph Hill Partners led the Series E round. All of its other existing institutional investors also participated in this round, including Psilos Group Management, QuestMark Partners, UV Partners, California Technology Ventures and Innomed Ventures.

Thomas Trotter, president and CEO of AngioScore, said the company would use the financing for international sales, manufacturing operations and new product development.

Thomas Weisel Partners, an investment banking firm, was the placement agent for the transaction.